How should I manage new‑onset peripheral edema with pitting in a patient with chronic kidney disease and an estimated glomerular filtration rate of 43 mL/min/1.73 m²?

Management of New-Onset Pitting Edema in CKD Stage 3b

In a patient with new-onset pitting edema and GFR 43 mL/min/1.73 m², you must first determine the underlying cause through targeted workup (urinalysis with albumin-to-creatinine ratio, serum albumin, and assessment of volume status), then optimize fluid management with diuretics while simultaneously ensuring the patient is on guideline-directed medical therapy including SGLT2 inhibitors and RAS inhibitors if not already prescribed.

Initial Diagnostic Approach

The presence of new-onset pitting edema in CKD Stage 3b requires immediate evaluation to distinguish between:

• Volume overload from declining kidney function and sodium retention
• Nephrotic syndrome (check serum albumin and urine protein-to-creatinine ratio)
• Cardiac causes (assess for heart failure symptoms)
• Medication-related edema (calcium channel blockers, NSAIDs)

The case report 1 highlights the importance of not dismissing lower extremity edema as simply "chronic" without proper workup, as nephrotic syndrome can present this way even in older patients.

Immediate Management Steps

1. Volume Assessment and Diuretic Therapy

Initiate or optimize loop diuretic therapy to address the fluid overload. At GFR 43, thiazide diuretics are less effective, and loop diuretics (furosemide, bumetanide, or torsemide) are the appropriate choice. The peritoneal dialysis study 2 demonstrates that persistent edema correlates with worse blood pressure control and indicates inadequate volume management, emphasizing the clinical importance of treating visible edema as a marker of hypervolemia.

2. Ensure Guideline-Directed Medical Therapy

According to KDIGO 2024 guidelines 3, this patient should be on:

SGLT2 Inhibitor: With GFR 43 and new edema (suggesting possible albuminuria or volume issues), an SGLT2i is strongly recommended (1A recommendation). These agents provide:

• Kidney protection
• Cardiovascular benefits
• Mild diuretic effect that may help with edema
• Should be initiated even at this GFR level (≥20 mL/min/1.73 m²)

RAS Inhibitor (ACEi or ARB): If not already prescribed, initiate for kidney protection. The KDIGO guideline 3 explicitly states to continue these agents even when eGFR falls below 30 mL/min/1.73 m², so GFR 43 is well within the treatment range. Monitor for:

• Creatinine rise >30% within 4 weeks (acceptable and not a reason to stop)
• Hyperkalemia (manage with dietary modification and potassium binders rather than stopping the RASi)

3. Blood Pressure Optimization

Target BP should be ≤130/80 mmHg 4. The edema itself indicates volume overload, which contributes to hypertension. Aggressive diuresis will help achieve BP targets while reducing edema.

4. Sodium Restriction

Limit sodium intake to <2 grams per day. This enhances the effectiveness of both diuretics and RAS inhibitors while reducing fluid retention 4.

Monitoring Parameters

After initiating or adjusting therapy:

• Serum creatinine and potassium: Check within 1-2 weeks after diuretic adjustment or RASi initiation
• Weight and edema assessment: Weekly initially to gauge diuretic response
• Blood pressure: Home monitoring if possible
• Urine albumin-to-creatinine ratio: If not recently checked, obtain to guide intensity of therapy 3

Common Pitfalls to Avoid

1. Do not discontinue RAS inhibitors due to mild creatinine elevation (<30% rise) or the GFR being in the 40s range 3
2. Do not withhold SGLT2 inhibitors at this GFR level; they are indicated down to GFR 20 3
3. Do not attribute edema solely to CKD without ruling out nephrotic syndrome, especially if serum albumin is low 1
4. Do not use thiazide diuretics alone at this GFR; loop diuretics are required for effective diuresis

Additional Considerations

If albuminuria is ≥200 mg/g (≥20 mg/mmol) despite maximum tolerated RASi and SGLT2i, consider adding a nonsteroidal mineralocorticoid receptor antagonist (finerenone) if potassium is consistently ≤4.8 mmol/L 3. This provides additional cardiorenal protection but requires careful potassium monitoring.

The presence of edema should prompt reassessment of the entire treatment regimen, medication compliance, and dietary sodium intake 2, as it represents a clinical marker of inadequate volume control that predicts worse cardiovascular outcomes.